Edwards Lifesciences Corporation $EW Holdings Boosted by Future Fund LLC

Future Fund LLC increased its stake in Edwards Lifesciences Corporation (NYSE:EW) by 11.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 22,585 shares of the medical research company’s stock after purchasing an additional 2,373 shares during the period. Future Fund LLC’s holdings in Edwards Lifesciences were worth $1,766,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Parkside Financial Bank & Trust boosted its position in shares of Edwards Lifesciences by 9.8% during the second quarter. Parkside Financial Bank & Trust now owns 1,455 shares of the medical research company’s stock worth $114,000 after buying an additional 130 shares during the period. Prosperity Consulting Group LLC increased its stake in shares of Edwards Lifesciences by 3.2% during the second quarter. Prosperity Consulting Group LLC now owns 4,304 shares of the medical research company’s stock valued at $337,000 after acquiring an additional 132 shares during the period. NewSquare Capital LLC increased its stake in shares of Edwards Lifesciences by 57.8% during the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 134 shares during the period. Dakota Wealth Management raised its holdings in Edwards Lifesciences by 2.5% during the second quarter. Dakota Wealth Management now owns 6,048 shares of the medical research company’s stock worth $473,000 after purchasing an additional 146 shares in the last quarter. Finally, LRI Investments LLC lifted its position in Edwards Lifesciences by 1.0% in the second quarter. LRI Investments LLC now owns 14,971 shares of the medical research company’s stock worth $1,171,000 after purchasing an additional 147 shares during the period. 79.46% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on EW shares. Oppenheimer downgraded Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research note on Wednesday, October 8th. Stifel Nicolaus boosted their price target on shares of Edwards Lifesciences from $85.00 to $95.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Edwards Lifesciences from $85.00 to $94.00 and gave the company a “buy” rating in a research report on Friday, July 25th. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $90.00 price objective on shares of Edwards Lifesciences in a research note on Monday, November 3rd. Finally, UBS Group reiterated a “neutral” rating and issued a $90.00 target price on shares of Edwards Lifesciences in a report on Monday, November 3rd. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Edwards Lifesciences presently has an average rating of “Moderate Buy” and an average price target of $91.39.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock opened at $83.37 on Friday. Edwards Lifesciences Corporation has a fifty-two week low of $64.89 and a fifty-two week high of $87.09. The firm’s 50 day simple moving average is $77.78 and its 200-day simple moving average is $77.36. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The company has a market cap of $48.95 billion, a P/E ratio of 12.00, a price-to-earnings-growth ratio of 3.97 and a beta of 1.03.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter in the prior year, the firm earned $0.67 EPS. The firm’s quarterly revenue was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. As a group, equities research analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Activity at Edwards Lifesciences

In other news, insider Larry L. Wood sold 8,950 shares of the firm’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider owned 206,900 shares of the company’s stock, valued at $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.